UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported) June 15, 2011
 
NOVAVAX, INC.

(Exact name of Registrant as specified in its charter)
 
Delaware
 
0-26770
 
22-2816046
(State or other jurisdiction of incorporation or organization)
 
(Commission File Number)
 
(I.R.S. Employer Identification No.)
 
9920 Belward Campus Drive
Rockville, Maryland
 
20850
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code:
 
(240) 268-2000
 

(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 5.07  Submission of Matters to a Vote of Security Holders.
 
Novavax, Inc. (the “Company”), held its Annual Meeting of Stockholders on June 15, 2011 (the “Annual Meeting”).  At the Annual Meeting, the Company’s stockholders elected Rajiv Modi, Ph.D. as a Class I director to serve on the Company’s Board of Directors until the Company’s 2014 Annual Meeting of Stockholders. The results of the stockholders’ votes with respect to the election of this director were as follows:
 
   
For
   
Withheld
   
Broker Non-Votes
 
Rajiv Modi
    53,694,594       993,775       35,346,541  
 
The Company’s stockholders voted to ratify the selection of Grant Thornton LLP as the Company’s independent auditor for the fiscal year ending December 31, 2011. The results of the stockholders’ votes with respect to this proposal were as follows:
 
   
For
   
Against
   
Abstain
 
Ratification of Independent Auditor
    89,168,781       618,360       247,769  
 
In addition, the Company’s stockholders also voted to increase by 3,000,000 shares the amount of shares that it may offer under the Company’s 2005 Stock Incentive Plan. The results of the stockholders’ votes with respect to this proposal were as follows:

   
For
   
Against
   
Abstain
   
Broker Non-Votes
 
Vote to increase the number of shares under the 2005 Stock Incentive Plan by 3,000,000
    50,944,114       3,550,222       3,550,222       35,346,541  

Finally, the Company’s stockholders provided two advisory votes.  Specifically the stockholders approved, on an advisory basis, the compensation paid to the Company’s Named Executive Officers in 2010, and further voted, on an advisory basis, as to the frequency with which the Company should seek approval of the stockholders for compensation paid to such Named Executive Officers. The results of these votes were as follows:

   
For
   
Against
   
Abstain
   
Broker Non-Votes
 
Vote to approve the 2010 compensation of Named Executive Officers
    52,633,424       1,735,695       319,250       35,346,541  
 
   
3 Years
   
2 Years
   
1 Year
   
Abstain
   
Broker Non-Votes
 
Frequency of vote to approve compensation of Named Executive Officers
    26,003,567       2,953,327       25,565,556       165,919       35,346,541  
 
 
2

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       
Novavax, Inc.
(Registrant)
 
         
June 21, 2011
     
By:
 
/s/ John A. Herrmann III
 
           
Name:
 
John A. Herrmann III
 
           
Title:
 
Executive Director, Legal Affairs and Corporate Secretary